Vaxcyte, Inc.
NASDAQ:PCVXBiotechnology
+$1.94 today
- Market cap
- $9.26B
- Beta
- 1.24
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$6.78
Volume 1.13M
Average 1.44M
PCVX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Vaxcyte, Inc.NASDAQ: PCVX
Total Equity · Q2 FY2026 · quarter ended Jun 2026
Total equity falls 10.2% from a year ago
Total equity stood at $2.76B at the end of Q2 FY2026, down 10.2% from a year earlier and down 7.9% from the prior quarter. Over 3 fiscal years it compounded at +41.2% a year.
Context
- Total equity amounted to 87.9% of total assets at the end of Q2 FY2026, down 5.0 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -10.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 2.69B USD
- Year-over-year change
- -18.8%
- 4-year CAGR
- +75.4%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.69B | -18.8% |
| FY2024 | 2024-12-31 | 3.31B | +166.5% |
| FY2023 | 2023-12-31 | 1.24B | +30.1% |
| FY2022 | 2022-12-31 | 953.61M | +235.8% |
| FY2021 | 2021-12-31 | 284.02M | — |
Total Equity vs competitors
How PCVX compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -10.2% is the 2nd highest of 9, against a peer median of -24.4%.
- Total equity amounts to 87.9% of total assets for PCVX, versus a peer median of 46.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $85.49B USD | -4.0% | -3.3% | 42.5% | |
| Jun 2026 | £17.07B GBP | -13.2% | +16.4% | 27.8% | |
| Sep 2026 | $6.84B USD | -26.7% | -23.2% | 50.8% | |
| Jun 2026 | $2.76B USD | -10.2% | +41.2% | 87.9% | |
| Mar 2026 | $812.77M USD | -22.1% | -28.3% | 79.2% | |
| Mar 2026 | $191.36M USD | -18.1% | -7.5% | 78.0% | |
| Mar 2026 | €76.78M EUR | -56.2% | -21.5% | 20.6% | |
| Mar 2026 | -$144.76M USD | -91.4% | — | 13.9% | |
| Sep 2026 | -$1.15B USD | -118.8% | — | 188.0% | |
| Peer median (excluding PCVX) | — | -24.4% | -14.5% | 46.6% | |
Competitors are the stored peer set for PCVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 68.99M | 834.66M | 397.45M | 387.88M | 173.96M |
| Short-term Investments | 176.99M | 96.72M | 682.78M | 1.36B | 1.39B |
| Net Receivables | 0 | 0 | 3.61M | 20.66M | 46.56M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 5.96M | 20.12M | 2.8M |
| Total Current Assets | 256.35M | 942.56M | 1.1B | 1.79B | 1.63B |
| Property, Plant & Equipment (Net) | 35.91M | 31.65M | 110.62M | 270.15M | 491.72M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 27.12M | 26.55M | 162.68M | 1.39B | 883.13M |
| Tax Assets | 0 | 0 | 0 | 0 | 43.25M |
| Other Non-current Assets | 4.96M | 5.43M | 38.67M | 65.68M | 508K |
| Total Non-current Assets | 67.99M | 63.62M | 311.96M | 1.72B | 1.42B |
| Total Assets | 324.34M | 1.01B | 1.41B | 3.51B | 3.05B |
| Account Payables | 6.76M | 9.8M | 14.59M | 48.45M | 70.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | 6.12M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.46M | 1.18M | 11.06M | 20.56M | 105.72M |
| Total Current Liabilities | 28.72M | 40.53M | 145.34M | 140.18M | 205.75M |
| Long-term Debt | 0 | 0 | 0 | 0 | 111.36M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 43.25M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 96K | 9K | 0 | 100K | (111.26M) |
| Total Non-current Liabilities | 11.6M | 12.04M | 22.11M | 65.32M | 154.7M |
| Total Liabilities | 40.32M | 52.57M | 167.45M | 205.5M | 360.46M |
| Common Stock | 56K | 82K | 98K | 128K | 134K |
| Retained Earnings | (298.64M) | (522.13M) | (924.39M) | (1.39B) | (2.15B) |
| Accumulated OCI | (241K) | (361K) | 179K | (3.87M) | 1.59M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 284.02M | 953.61M | 1.24B | 3.31B | 2.69B |
| Total Debt | 16.78M | 17.94M | 29.22M | 71.11M | 228.84M |
| Net Debt | (52.2M) | (816.72M) | (368.23M) | (316.77M) | 54.88M |
Vaxcyte, Inc.
NASDAQ:PCVX
Intrinsic Alpha fair value
Locked
Current Price
$58.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.